Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic immune thrombocytopenia
Biotech
Takeda's anti-CD38 antibody boosts platelet count in phase 2
Takeda pruned mezagitamab's potential, but the company used new data to argue the anti-CD38 antibody could still “transform treatment” of ITP.
James Waldron
Jun 24, 2024 8:58am
Sanofi nails phase 3 LUNA landing, sparking race to regulators
Apr 23, 2024 2:23am
Hutchmed eyes China approval for autoimmune drug after ph. 3 win
Aug 21, 2023 8:45am